Intervention in at-risk states for developing psychosis

  • Stephan Ruhrmann
  • Frauke Schultze-Lutter
  • Andreas Bechdolf
  • Joachim Klosterkötter
Review

Abstract

Indicated prevention is currently one of the most promising approaches to fight the individual and societal burden associated with psychosis and particularly schizophrenia. The number of studies is still limited, yet encouraging results have been reported from pharmacological and psychotherapeutic trials. Furthermore, it has become clear that persons characterized by the at-risk criteria are already ill and do not only need preventive intervention but also treatment. As is indicated by a recent study successfully using omega-3 fatty acids for both purposes, it may be promising to develop and investigate interventions especially for the at-risk state, independent of their effectiveness in manifest disease states. An overview on the current findings and ongoing research in this area is provided.

Keywords

Prevention of psychosis Ultra-high risk Prodrome Basic symptoms Early intervention 

References

  1. 1.
    Amminger GP, Schafer MR, Papageorgiou K et al (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154CrossRefPubMedGoogle Scholar
  2. 2.
    APA (2010) DSM-V development: proposed draft revisions to DSM disorders and criteria. http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx? rid = 412. Accessed 8 July 2010
  3. 3.
    Bechdolf A, Ruhrmann S, Wagner M et al (2005) Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry Suppl 48:s45–s48CrossRefGoogle Scholar
  4. 4.
    Bechdolf A, Veith V, Vogeley K et al (2008) PREVENT: background and rational of a clinical study comparing the preventive effects of CBT, aripriprazole and placebo in persons at-risk for psychosis. Early Interv Psychiatry 2(Suppl 1):11Google Scholar
  5. 5.
    Berger G, Wood S, Ross M et al (2008) Neuroprotective effects of low dose lithium in individuals at ultra-high risk for psychosis. Early Interv Psychiatry 2:A28Google Scholar
  6. 6.
    Cornblatt BA, Lencz T, Smith CW et al (2007) Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 68:546–557CrossRefPubMedGoogle Scholar
  7. 7.
    Fusar-Poli P, Valmaggia L, McGuire P (2007) Can antidepressants prevent psychosis? Lancet 370:1746–1748CrossRefPubMedGoogle Scholar
  8. 8.
    Häfner H, an der Heiden W (2008) Course and Outcome. In: Mueser KT, Jeste DV (eds) Clinical handbook of schizophrenia. The Guilford Press, New York, NY, pp 100–113Google Scholar
  9. 9.
    Haynes RB, Sackett DL, Guyatt GH et al (2006) Clinical epidemiology. Lippincott Williams & Williams, PhiladelphiaGoogle Scholar
  10. 10.
    Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276PubMedGoogle Scholar
  11. 11.
    Klosterkötter J (2008) Indicated prevention of schizophrenia. Dtsch Arztebl Int 105:532–539PubMedGoogle Scholar
  12. 12.
    Klosterkötter J, Hellmich M, Steinmeyer EM et al (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiat 58:158–164CrossRefPubMedGoogle Scholar
  13. 13.
    Kuipers E, Bebbington P (2006) Cognitive behaviour therapy for psychosis. Epidemiol Psichiatr Soc 15:267–275PubMedGoogle Scholar
  14. 14.
    Kumra S, Oberstar JV, Sikich L et al (2008) Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34:60–71CrossRefPubMedGoogle Scholar
  15. 15.
    McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiat 163:790–799CrossRefPubMedGoogle Scholar
  16. 16.
    McGorry PD, Hickie IB, Yung AR et al (2006) Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 40:616–622PubMedGoogle Scholar
  17. 17.
    McGorry PD, Nelson B, Amminger GP et al (2009) Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry 70:1206–1212CrossRefPubMedGoogle Scholar
  18. 18.
    McGorry PD, Yung AR, Phillips LJ et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiat 59:921–928CrossRefPubMedGoogle Scholar
  19. 19.
    Moreno C, Arango C, Parellada M et al (2007) Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiat Scand 115:184–195CrossRefPubMedGoogle Scholar
  20. 20.
    Morrison AP, French P, Bentall RP et al (2008) Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Interv Psychiatry 2:A15Google Scholar
  21. 21.
    Morrison AP, French P, Parker S et al (2007) Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 33:682–687CrossRefPubMedGoogle Scholar
  22. 22.
    Morrison AP, French P, Walford L et al (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Brit J Psychiat 185:291–297CrossRefPubMedGoogle Scholar
  23. 23.
    Nuechterlein KH (1987) Vulnerability models for schizophrenia: State of the art. In: Häfner H, Gattaz WF, Janzarik W (eds) Search for the causes of schizophrenia. Springer, Heidelberg, pp 297–316Google Scholar
  24. 24.
    O’Brien MP, Zinberg JL, Bearden CE et al (2007) Psychoeducational multi-family group treatment with adolescents at high risk for developing psychosis. Early Interv Psychiatry 1:325–332CrossRefGoogle Scholar
  25. 25.
    O’Brien MP, Zinberg JL, Ho L et al (2009) Family problem solving interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis and with recent onset psychotic symptoms: a longitudinal study. Schizophr Res 107:198–205CrossRefPubMedGoogle Scholar
  26. 26.
    Papakostas GI (2008) Tolerability of modern antidepressants. J Clin Psychiatry 69(Suppl E1):8–13PubMedGoogle Scholar
  27. 27.
    Phillips LJ, McGorry PD, Yuen HP et al (2007) Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 96:25–33CrossRefPubMedGoogle Scholar
  28. 28.
    Phillips LJ, Nelson B, Yuen HP et al (2009) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiat 43:818–829CrossRefGoogle Scholar
  29. 29.
    Rietdijk J, Dragt S, Klaassen R et al (2010) A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials 11Google Scholar
  30. 30.
    Ruhrmann S, Bechdolf A, Kuhn KU et al (2007) Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 51:S88–S95CrossRefPubMedGoogle Scholar
  31. 31.
    Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2010) Probably at-risk, but certainly ill—Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 120:23–37Google Scholar
  32. 32.
    Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2003) Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36(Suppl 3):S162–S167PubMedGoogle Scholar
  33. 33.
    Ruhrmann S, Schultze-Lutter F, Salokangas RK et al (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251CrossRefPubMedGoogle Scholar
  34. 34.
    Schultze-Lutter F, Ruhrmann S, Berning J et al (2010) Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 36:182–191CrossRefPubMedGoogle Scholar
  35. 35.
    Schultze-Lutter F, Ruhrmann S, Klosterkötter J (2006) Can schizophrenia be predicted phenomenologically? In: Johannesen JO, Martindale BV, Cullberg J (eds) Evolving psychosis: different stages, different treatments. Routledge, Hove, pp 104–123Google Scholar
  36. 36.
    Simon AE, Dvorsky DN, Boesch J et al (2006) Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res 81:83–90CrossRefPubMedGoogle Scholar
  37. 37.
    Svirskis T, Korkeila J, Heinimaa M et al (2005) Axis-I disorders and vulnerability to psychosis. Schizophr Res 75:439–446CrossRefPubMedGoogle Scholar
  38. 38.
    HO W (2004) Prevention of mental disorders : effective interventions and policy options. World Helath Organization, GenevaGoogle Scholar
  39. 39.
    Wood SJ, Berger GE, Dell’Olio M et al (2007) Effects of low dose lithium on hippocampal neuropathology in people at ultra-high risk for psychosis. Biol Psychiat 61:259s–260sGoogle Scholar
  40. 40.
    Woods SW, Breier A, Zipursky RB et al (2003) Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiat 54:453–464CrossRefPubMedGoogle Scholar
  41. 41.
    Woods SW, Tully EM, Walsh BC et al (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 51:s96–s101CrossRefPubMedGoogle Scholar
  42. 42.
    Woods SW, Walsh B, Pearlson GD et al (2006) Glycine treatment of prodromal symptoms. Schizophr Res 86(Suppl):S7Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Stephan Ruhrmann
    • 1
  • Frauke Schultze-Lutter
    • 2
  • Andreas Bechdolf
    • 1
  • Joachim Klosterkötter
    • 1
  1. 1.Department of Psychiatry and PsychotherapyUniversity of CologneCologneGermany
  2. 2.University Hospital of Child and Adolescent PsychiatryUniversity of BernBernSwitzerland

Personalised recommendations